Hormone therapy plus local treatment for advanced prostate cancer
Part of Cancer clinical trials.
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have a type of prostate cancer that has spread to other parts of your body and is still sensitive to hormone therapy (called metastatic hormone-sensitive prostate cancer).
- A special scan called a PSMA PET/CT shows that the cancer is still active even after you started hormone therapy.
- You have not had any other treatment for your prostate cancer before this study.
- You are generally in good health (able to care for yourself and up and about at least half the day).
- You have no other active cancer in the last 2 years (except certain skin or bladder cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
This trial is testing whether adding a new hormone pill called rezvilutamide to the usual treatment (hormone therapy plus surgery and targeted radiation) can better control prostate cancer that has spread to a few small spots.
This trial is testing whether giving prostate removal surgery in addition to standard hormone therapy can help men with advanced prostate cancer that has spread to many places. It aims to see if this combination helps them live longer with a better quality of life.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.